By Fineline Cube 
China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its in-house developed recombinant tetanus vaccine (Escherichia coli). This marks a significant step forward in the development of a new-generation vaccine for the prevention of tetanus.
Vaccine Innovation
The recombinant tetanus vaccine was co-developed with the Academy of Military Medical Sciences and represents a new-generation recombinant vaccine based on genetic engineering. Unlike traditional toxoid vaccines currently in use in China and globally, this vaccine offers a modern approach to tetanus prevention. Currently, there is no similar product approved anywhere in the world, highlighting the innovative nature of this development.
Market Landscape
Only two companies are currently testing genetic engineering-based recombinant tetanus vaccines in clinical trials. North China Pharmaceutical’s entry into this space underscores its commitment to advancing vaccine technology and addressing unmet needs in tetanus prevention.-Fineline Info & Tech